The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "psoriasis"

Search results for: psoriasis

Tofacitinib on Hold for Psoriasis, Plus Anti-TNFs Top FDA List for Adverse Events

October 28, 2015 • By Michele B. Kaufman, PharmD, BCGP

The FDA is asking for more safety analysis before approving tofacitinib to treat psoriasis. Also, adalimumab and etanercept received the greatest number of adverse and serious adverse events reported to the FDA in 2014…... [Read More]

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, adverse event, Anti-TNF, etanercept, FDA, Food and Drug Administration, Institute for Safe Medication Practices, plaque psoriasis, Tofacitinib, tofacitinib citrate

Psoriasis Tied to Increased Risk of Major Depression

October 8, 2015 • By Will Boggs, MD

NEW YORK (Reuters Health)—People with psoriasis are twice as likely as others to have major depression, according to data from the National Health and Nutrition Examination Survey (NHANES). In earlier work, psoriasis has been linked to depression, anxiety and substance abuse. Studies have shown that both depression and psoriasis are associated with cardiovascular disease, which… [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Depression, Mental Health, Psoriasis

Patients with Psoriasis, Psoriatic Arthritis at Increased Risk of Migraine

October 4, 2015 • By Shannon Aymes

NEW YORK (Reuters Health)—Psoriasis and psoriatic arthritis are associated with an increased risk of migraine, according to new research from Denmark. “The main finding of our study was a psoriasis severity-dependent increased risk of new-onset migraine, and patients with severe skin psoriasis and psoriatic arthritis appeared to have the highest risk,” Dr. Alexander Egeberg from… [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Migraine, Psoriasis, Psoriatic Arthritis

Guselkumab Studied to Treat RA, Plaque Psoriasis

September 15, 2015 • By Michele B. Kaufman, PharmD, BCGP

Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against… [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: biosimilar, clinical trial, Drugs, guselkumab, outcome, plaque psoriasis, Rheumatoid arthritis, rheumatology, Safety

XenoPort’s Psoriasis Drug Found Effective in Phase 2 Trial

September 15, 2015 • By Reuters Staff

(Reuters)—Drug developer XenoPort Inc. said on Tuesday its experimental drug was effective in treating psoriasis, sending its shares up 19% in premarket trading. The oral drug met the main goal in a phase 2 trial of patients with moderate-to-severe chronic plaque-type psoriasis, the company said. XenoPort said it expected to start late-stage trials next year… [Read More]

Filed Under: Drug Updates Tagged With: brodalumab, plaque psoriasis, Psoriasis, Psoriatic Arthritis, secukinumab, XenoPort Inc., XP23829

Ustekinumab Found to Be Effective in Adolescents with Psoriasis

August 27, 2015 • By Rob Goodier

NEW YORK (Reuters Health)—Adolescents with moderate to severe psoriasis may respond to the human monoclonal antibody ustekinumab as well as adults, with no unexpected side effects, a new study found. The findings are exciting in part because patients in this age group have limited treatment options, the study’s lead author Dr. Ian Landells, of Memorial… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Adolescents, Psoriasis, ustekinumab

Adalimumab Remains Safe, Effective for Psoriasis

July 30, 2015 • By Scott Baltic

NEW YORK (Reuters Health)—In adults with chronic plaque psoriasis, adalimumab (Humira, AbbVie) was generally well tolerated and effective during five years of therapy, according to a new analysis. The interim analysis is from ESPRIT, a 10-year multinational post-marketing registry. “Clinical trials are not the real world,” in part because patients with comorbidities are screened out… [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: adalimumab, plaque psoriasis

Psoriasis, Psoriatic Arthritis Linked with Arrhythmia

July 29, 2015 • By Laura Newman

NEW YORK (Reuters Health)—Psoriasis is linked to a higher risk for arrhythmia, independent of classic cardiovascular (CV) risk factors, according to a study from Taiwan. “In my practice, arrhythmia as comorbidity is discussed during patient consultation along with other comorbidities,” said senior author Dr. Tsen-Fang Tsai of the Department of Dermatology at National Taiwan University… [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: arrhythmia, heart, National Psoriasis Foundation, Psoriasis

Evidence Lacking for Tests for Psoriasis Patients Using Biologic Agents

July 25, 2015 • By Will Boggs, MD

NEW YORK (Reuters Health)—Various organizations recommend dozens of screening and monitoring tests for patients with psoriasis or psoriatic arthritis who are using systemic biologic agents, despite sparse evidence to support any of them. “At a population level, these medications have proven to be very safe and the evidence does not support such extensive and frequent… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics, infliximab, Psoriasis, Psoriatic Arthritis

Adverse Event Risk Data Drive Evaluation of Psoriasis Treatments

July 14, 2015 • By Michele B. Kaufman, PharmD, CGP, RPh

PSOLAR, the Psoriasis Longitudinal Assessment and Registry, is a multicenter, longitudinal, intercontinental, disease-based registry used to identify adverse events from commonly used psoriasis drugs.1 An evaluation of the risk of serious infection from systemic psoriasis treatments was recently published using data from PSOLAR. Ninety-three institutional review boards or ethics committees reported into the registry from… [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: adverse event, brodalumab, clinical trial, data, drug, outcome, Psoriasis, rheumatology, risk, Safety

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 43
  • Next Page »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.